Oppenheimer Turns Bullish on Savara as Molgramostim Moves Closer to Approval
Savara gets FDA priority review for its drug, analyst raises target to $11, sees strong approval chances and upside.
/ 124 items
#XY Analyst Up/Down↓
JPMorgan Gives Hims & Hers a $35 Bullish Rating – Full GLP-1 Lineup Just Got Even Stronger
JPMorgan backs Hims & Hers Health as a strong buy, boosted by GLP-1 drugs and big deals with Novo Nordisk and Eli Lilly.
Mizuho Upgrades Outlook: Harmony’s Wakix Now Protected Until 2030
Harmony Biosciences wins key patent lawsuit, protecting Wakix from generics until ~2030; analyst stays positive with $50 target.
Compass Pathways Surges as BTIG Reaffirms Buy Rating and Trump’s Psychedelic Executive Order Sparks Sector Rally
BTIG raises CMPS to Buy, $14 target; stock jumps 42% after Trump boosts psychedelic research funding and faster FDA paths.
Wall Street Backs Achieve Life Sciences: Cytisinicline Labeled 'Best-in-Class' Smoking Cessation Drug
Achieve Life Sciences gets Buy rating as its quit-smoking drug cytisinicline shows strong results; FDA decision due June 2026.
Cantor Fitzgerald Calls Candel Therapeutics Deeply Undervalued – Overweight Rating Initiated
Cantor is very bullish on CADL, sees big undervaluation and CAN-2409 as a major drug with huge growth potential.